Japan and South Korea are part of a complex and tightly linked supply chain that produces electronic goods such as smartphones and laptops.Technologyread more
A different oil pricing dynamic has been evolving with new supply calculations based on the U.S. as the world's largest producer.Market Insiderread more
The Massachusetts senator's alarm-sounding on consumer debt neglects to measure it against the growth in the economy and the ability to pay.Economyread more
Stocks in Asia Pacific edged up on Tuesday morning following overnight gains on Wall Street as the earnings season rolls on.Asia Marketsread more
More than half of Venezuela's 23 states lost power on Monday, according to Reuters witnesses and reports on social media, a blackout the government blamed on an...World Politicsread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
The deal between the White House and Democrats was earlier expected to raise the debt ceiling for two years and permanently end the sequester.Politicsread more
Britain's Antstream is jumping into the cloud gaming battle with a streaming platform for retro titles. And Tencent just backed the company.Technologyread more
American comedian Hannibal Buress, who stars in "The Eric Andre Show," has made a recent transition into the world of business as an angel investor — but there's an important...How I Made Itread more
The deal could be announced as soon as next week, according to the report.Technologyread more
President Donald Trump held "constructive" discussions on a range of economic issues including trade and national security issues.Technologyread more
Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market.
The U.S. Food and Drug Administration (FDA) approved a 40 milligrams per milliliter injection of the Novartis copy of Copaxone, Teva's blockbuster medicine, Sandoz said in a statement on Tuesday.
Sandoz began selling a 20 mg/ml Glatopa dosage to U.S. patients with relapsing MS in 2015 but missed out on millions of dollars in sales after the double-dosage version was pushed back last year after contamination problems at the Pfizer fill-and-finish plant being used by Sandoz.
The FDA approval, which Novartis had expected in the second half of this year, could help to compensate for the recent FDA delay of a Sandoz version of GlaxoSmithKline's asthma and COPD drug Advair, analysts said. The drug's launch is now unlikely before 2019.
"The earlier than expected authorization (of Glatopa) and commercial launch might add an estimated $200 million to Sandoz' 2018 top line, translating in a low-single-digit divisional growth," said Baader Helvea analyst Bruno Bulic.
"We see ... Glatopa 40mg offsetting the Advair setback and reiterate our buy rating."
Novartis developed Glatopa with Massachusetts-based Momenta Pharmaceuticals.
The Pfizer plant problems scuttled plans to have the larger Glatopa dosage on sale first in 2017, allowing Mylan to muscle in on lucrative market share with its quicker-to-market Copaxone copy.
Pfizer said last month that the FDA had upgraded the compliance status of its Kansas facility, clearing the way for the Novartis-Momenta medicine.
Overall, Sandoz has been a drag on Novartis results in recent months, with its pills portfolio particularly sensitive to U.S. price pressure. The division's sales fell 1 percent last year to $10.1 billion and Novartis expects sales to be dented by stagnating or declining revenue at Sandoz in 2018.
Novartis is reviewing Sandoz's U.S. pills business for a potential disposal and aims to focus on more complex injectible drugs in its generics portfolio, such as Glatopa, as well as biosimilars.
"The approval and launch of Glatopa 40 mg/mL reinforces our leadership in delivering complex, differentiated generic products," Sandoz head Richard Francis said in a statement.